CONFIDENTIAL


亚太原油基准展望

Christopher Fix, DME首席执行官 2014年5月



DME是一个总部位于迪拜的商品交易所,以促进中东的贸易







WTI & 布伦特诞生的原因

在1981年早期美国价格管制的结束,允许市场更自由地交易。

1

在20世纪70年代-80年代,波斯湾地区众多外交和军事问题所造成的巨大的价格波动,鼓励石油市场参与者做对冲。

2

伦敦和纽约银行鼓励套期保值和参与交易 – 原油成为一种资产类别

3



1982

NYMEX (之后为CME 集 团) 上市 WTI 1986

IPE (之后为洲际交易所) 上市布伦特


之后,亚洲随着...



亚洲需求的上升导致石油市场的结构性变化



1 新的价格水平的建立



SOURCE: BP Statistical Review

原油期货已证实在亚洲的难度 近15年来15个原油期货合约在亚洲推出





中东含硫原油失败



WTI流动量很好,但是布伦特已经 终止交易



中东含硫原油失败



中东含硫原油交易量下降



WTI很小,但仍幸存,布伦 特已经终止交易



中东含硫原油失败



TFEX布伦特几乎接近终止 交易



2个原油合约均失败并终止交易



DGCX B布伦特合约失败; WTI 流动性很差




交易量和持仓量新纪录

15个合约当中有3个合约交易量还不错,之后DME在增长...

DME阿曼已经看到交易量自上市以来持续增长








2014年平均每月交割1500万桶

实物交割量(2007 - 2014), '000 桶/月



为什么许多其他亚洲原油合约会失败?



INE将有类似的优势-它将会是实物交割的原始合约,而不是复制的。

许多是现金结算-这对有现货背景 的原油公司的吸 引力很小。

> 很多是复制合约-难以 鼓动亚洲交易员在当 地亚洲交易所交易布 伦特或者WTI, 当原始 合约的流动性非常 好。

DME的优点是它提供的是全新的产品 -实物交割的阿曼 原油



能源合约通常不像 黄金和股票指数那 样吸引亚洲散户。

仍在探讨更多亚洲原油合约





INE的机会是明确的



1

很明确的亚洲原油需要一个新的基准

7

加强全球监管鼓励市场走向期货的模式,特别是对基准定价

3

中国期货交易所已经建立了成功的业绩

4

DME已证实现货交割的原油对亚洲非常有吸引力

5

DME-INE的差价将反映来自波斯湾的进口原油 到中国(运费,保险,外汇等)的市场经济,使得两个合约互相照应调整


期货交易员偏爱关注差价交易





下一个主要原油差价交易将是INE vs DME







- 期货是大宗商品定价的"黄金标准"
- 很多交易所在亚洲都尝试推出原油期货合约,但都失败了。
- · DME仍然很小,但是它是唯一增长的亚洲原油合约
- · INE的合约设计理念和DME相似,应该会成功。
- 差价交易将有利于双方交易所。
- 亚洲需要有自己的定价基准。



Disclaimer



- The information in this document is being communicated by the Dubai Mercantile Exchange Limited (DME), regulated by the Dubai Financial Services Authority (DFSA) and is directed at wholesale customers as defined by the DFSA. The financial products to which the document relates will only be made available to wholesale customers who the DME is satisfied meets the regulatory criteria to be a client of the DME.
- This document has been prepared solely for information purposes and should not form the basis of, or be relied on in connection with, any investment decision or any contract or commitment whatsoever with respect to any proposed transaction or otherwise.
- This document was prepared based solely on information obtained from public sources on or prior to the date hereof. The DME has assumed and relied upon, without independent verification, the accuracy and completeness of the information reviewed by us for the purposes of this presentation. No representation or warranty, express or implied, is or will be made to wholesale customers or its affiliates or to any of their respective officers, employees or agents in relation to the accuracy or completeness of the information contained in this document, or any oral information provided in connection therewith and, without prejudice to any liability for fraudulent misrepresentation, no responsibility, obligation or liability (whether direct or indirect, in contract, tort or otherwise) is or will be accepted by any of them in relation to such information. DME and its respective officers, employees or agents expressly disclaim any and all liability which may be based on this document and any errors therein or omissions there from. In particular, no representation or warranty, express or implied, is given as to the achievement or reasonableness of future projections, management targets, estimates, prospects or returns, if any.
- Any views contained herein are based on financial, economic, market and other conditions prevailing as of the date of this presentation.
- This document does not constitute and should not be considered as any form of financial opinion or recommendation on the part of DME or any of its subsidiaries or associated companies.
- DME's listing of any new contracts is subject to approval by DFSA and other relevant regulators as well as the fulfillment of the other requirements set out in the DME Rulebook. Furthermore, all clearing and settlement services to be provided by the New York Mercantile Exchange to DME for new contracts is subject to approval by the Commodity Futures Trading Commission.